Latest Affinium Pharmaceuticals Stories

2014-02-11 08:33:36

LAUSANNE, Switzerland, February 11, 2014 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, and Affinium Pharmaceuticals (Affinium), a Canadian company focusing on the development of a platform of novel, targeted narrow-spectrum antibacterial therapeutics, today announced the acquisition by Debiopharm of Affinium's clinical and...

2011-05-02 09:35:00

AUSTIN, TEXAS, May 2 /PRNewswire/ - Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The study examined the tolerability, safety and pharmacokinetics of immediate release tablets of AFN-1252. Cohorts of healthy volunteers were dosed 200mg, 300mg, and 400 mg of AFN-1252 once daily for 10 days. The pharmacokinetic results indicate that...

2011-03-15 07:28:00

AUSTIN, March 15 /PRNewswire/ - Affinium Pharmaceuticals, a clinical-stage drug development company with a novel, specific-spectrum anti-staphylococcal antibiotic, announced today that Dr. Barry Hafkin, Chief Medical Officer, and Dr. Nachum Kaplan, Vice President of Microbiology, will present at the 13(th) Annual Super Bugs and Super Drugs conference in London, England on March 16-17, 2011. Dr Kaplan will be speaking on development of a novel, specific-spectrum, oral antibiotic for...

Word of the Day
  • Color; hue; complexion.
This word is Middle English in origin.